# US 2013/0287874 A1 · Spoonable yogurt preparations containing non-replicating probiotic micro-organisms

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0287874 A1
- Document ID: US20130287874A1
- Status: Published application
- Kind: A1
- Application number: 13/884,539
- Filed: 2011-11-10
- Published: 2013-10-31
- Earliest claimed: 2010-11-11
- Assignees: Nestec S.A.
- Inventors: Annick Mercenier; Guenolee Prioult; Sophie Nutten
- Web page: https://patentgrep.com/patent/US20130287874A1

## CPC

- A23C 9/123: using only microorganisms of the genus lactobacteriaceae; Yoghurt (A23C9/13 takes precedence)
- A23C 9/1234: {characterised by using a Lactobacillus sp. other than Lactobacillus Bulgaricus, including Bificlobacterium sp.}
- A61K 35/741: Probiotics (probiotic yeast, e.g. saccharomyces A61K36/06)
- A61K 35/745: Bifidobacteria
- A61K 35/747: Lactobacilli, e.g. L. acidophilus or L. brevis
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 37/02: Immunomodulators
- A23V 2400/151: Johnsonii
- A23V 2400/157: Lactis
- A23V 2400/175: Rhamnosus
- A23V 2400/425: Paravulus
- A23V 2400/533: Longum
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A23C: DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; PREPARATION THEREOF (preservation thereof A23B11/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A23V: INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present invention relates to the field of spoonable yogurt compositions. In particular, the present invention provides spoonable yogurt compositions comprising non-replicating probiotic micro-organisms. These non-replicating probiotic micro-organisms may be bioactive heat treated probiotic micro-organisms, for example. The present invention also relates to health benefits provided by these non-replicating probiotic micro-organisms.

## Claims

### Claim 1

Spoonable yogurt composition comprising non-replicating probiotic micro-organisms.

### Claim 2 (depends on 1)

Spoonable yogurt composition in accordance with claim 1 comprising about 106 to 1012 cfu per serving of non-replicating probiotic micro-organisms.

### Claim 3 (depends on 1)

Spoonable yogurt composition in accordance with claim 1 wherein the composition is to be stored under chilled or ambient temperatures.

### Claim 4 (depends on 1)

Spoonable yogurt composition in accordance with claim 1 comprising prebiotics.

### Claim 5 (depends on 1)

Spoonable yogurt composition in accordance with claim 1, wherein the probiotic micro-organisms were rendered non-replicating by a heat-treatment.

### Claim 6 (depends on 5)

Spoonable yogurt composition in accordance with claim 5, wherein the heat treatment is a high temperature treatment at about 71.5-150° C. for about 1-120 seconds.

### Claim 7

A method for the prevention or treatment of inflammatory disorders comprising administering to an individual in need of same a spoonable yogurt composition comprising non-replicating probiotic micro-organisms.

### Claim 8 (depends on 7)

Method in accordance with claim 7, wherein the heat treatment is performed at a the temperature of about 70-150° C. for about 3 minutes-2 hours.

### Claim 9

A method for the prevention or treatment disorders related to a compromised immune defense comprising administering to an individual in need of same a spoonable yogurt composition comprising non-replicating probiotic micro-organisms.

### Claim 10 (depends on 1)

Spoonable yogurt composition in accordance with claim 1 wherein at least 90% of the probiotics are non-replicating.

### Claim 11 (depends on 1)

Spoonable yogurt composition in accordance with claim 1 wherein the probiotic micro-organisms are selected from the group consisting of bifidobacteria, lactobacilli, propionibacteria, or combinations thereof, for example Bifidobacterium longum, Bifidobacterium lactis, Bifidobacterium animalis, Bifidobacterium breve, Bifidobacterium infantis, Bifidobacterium adolescentis, Lactobacillus acidophilus, Lactobacillus casei, Lactobacillus paracasei, Lactobacillus salivarius, Lactobacillus reuteri, Lactobacillus rhamnosus, Lactobacillus johnsonii, Lactobacillus plantarum, Lactobacillus fermentum, Lactococcus lactis, Streptococcus thermophilus, Lactococcus lactis, Lactococcus diacetylactis, Lactococcus cremoris, Lactobacillus bulgaricus, Lactobacillus helveticus, Lactobacillus delbrueckii, Escherichia coli and mixtures thereof.

### Claim 12 (depends on 1)

Spoonable yogurt composition in accordance with claim 1 wherein the probiotic micro-organisms are selected from the group consisting of Bifidobacterium longum NCC 3001, Bifidobacterium longum NCC 2705, Bifidobacterium breve NCC 2950, Bifidobacterium lactis NCC 2818, Lactobacillus johnsonii La1, Lactobacillus paracasei NCC 2461, Lactobacillus rhamnosus NCC 4007, Lactobacillus reuteri DSM17938, Lactobacillus reuteri ATCC55730, Streptococcus thermophilus NCC 2019, Streptococcus thermophilus NCC 2059, Lactobacillus casei NCC 4006, Lactobacillus acidophilus NCC 3009, Lactobacillus casei ACA-DC 6002 (NCC 1825), Escherichia coli Nissle, Lactobacillus bulgaricus NCC 15, Lactococcus lactis NCC 2287, and combinations thereof.

### Claim 13 (depends on 1)

Spoonable yogurt composition in accordance with claim 1 containing about 0.005 mg-1000 mg non-replicating micro-organisms per daily dose.
